Followers | 144 |
Posts | 27709 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, September 10, 2020 1:27:49 AM
3 analysts offering their estimates for the company have set an average revenue estimate of $25.63 Million for the current quarter. 3 have an estimated revenue figure of $33.86 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $1.4 Million for this quarter, and analysts expect sales will grow by 1729.4% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.9% over the past 5 years. Earnings growth for 2020 is a modest +15.1%.
RedHill Biopharma Ltd. (NASDAQ:RDHL)’s Major holders
Insiders own 15.37% of the company shares, while shares held by institutions stand at 20.91% with a share float percentage of 24.71%. Investors are also buoyed by the number of investors in a company, with RedHill Biopharma Ltd. having a total of 53 institutions that hold shares in the company. The top two institutional holders are Disciplined Growth Investors, Inc. with over 2.12 Million shares worth more than $14.19 Million. As of June 29, 2020, Disciplined Growth Investors, Inc. held 6% of shares outstanding.
The other major institutional holder is Ibex Investors LLC, with the holding of over 1.87 Million shares as of June 29, 2020. The firm’s total holdings are worth over $12.53 Million and represent 5.3% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Israel Innovative Technology ETF and ETF Managers Tr-BlueStar TA-BIGI Tech Israel Technology ETF. As of April 29, 2020, the former fund manager holds about 0.19% shares in the company for having 65400 shares of worth $469.57 Thousand while later fund manager owns 59.36 Thousand shares of worth $397.68 Thousand as of June 29, 2020, which makes it owner of about 0.17% of company’s outstanding stock.
https://marketingsentinel.com/2020/09/09/how-is-the-redhill-biopharma-ltd-nasdaqrdhl-performance-outlook-for-the-coming-months-2/
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/18/2024 01:00:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/17/2024 01:13:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 11:04:47 AM
- RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines • PR Newswire (US) • 09/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/05/2024 12:30:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/05/2024 11:05:46 AM
- RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 09/05/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/03/2024 11:03:23 AM
- New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality • PR Newswire (US) • 09/03/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 11:07:16 AM
- RedHill Biopharma Announces First Half 2024 Business Highlights • PR Newswire (US) • 08/29/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 11:02:21 AM
- RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma • PR Newswire (US) • 08/26/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 11:04:32 AM
- Talicia® Launched in the United Arab Emirates • PR Newswire (US) • 08/21/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/20/2024 04:15:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 11:01:08 AM
- RedHill Announces Positive Obesity and Diabetes Results with Opaganib • PR Newswire (US) • 08/19/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 11:13:47 AM
- RedHill Biopharma Announces Plan to Implement ADS Ratio Change • PR Newswire (US) • 08/16/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/13/2024 05:37:51 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:35:44 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/09/2024 11:01:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/07/2024 01:51:39 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM